INNATE PHARMA SA (IPHA) News

INNATE PHARMA SA (IPHA): $4.10

0.24 (+6.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IPHA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 481

in industry

Filter IPHA News Items

IPHA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IPHA News Highlights

  • IPHA's 30 day story count now stands at 4.
  • Over the past 15 days, the trend for IPHA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • AGM, TEL and DE are the most mentioned tickers in articles about IPHA.

Latest IPHA News From Around the Web

Below are the latest news stories about Innate Pharma SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.

Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business Update

Marseille, France, May 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, May 11, 2021 at 3 p.m. CEST / 9 a.m. ET, to give an update on business progress during the first quarter of 2021. Participating in the call will be Innate Pharma’s Chief Executive Officer Mondher Mahjoubi, MD, Chief Medical Officer Joyson Karakunnel, MD, MSc, FACP, and Chief Financial Officer Frédéric Lombard, MBA. Details for the Virtual Event The live webcast will be available at the following link: https://edge.media-server.com/mmc/p/o65bcx4w Participants may also join via telephone to ask questions by registering in advance of the event at http://emea.direct...

Yahoo | May 4, 2021

Innate Pharma Files Its 2020 Universal Registration Document (Document D’enregistrement Universel) and 2020 Annual Report on Form 20-F

MARSEILLE, France, April 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2020 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2020 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 27, 2021. It can be downloaded (in French) on the Company’s website and on the AMF’s website. The Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2020 with the United States Securities and Exchange Commission (“SEC”). It can be also be accessed on the Company’s website and on the SEC’s website. About Innate Pharma: Innate Pharma S.A. is a global, cl...

Yahoo | April 28, 2021

Innate Pharma to Hold its Annual General Meeting of Shareholders on May 28, 2021

The Annual General Meeting will be broadcasted live by the Company Shareholders are invited to vote at the General Meeting either by mail or by proxy Marseille, France, April 21, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of Shareholders (“AGM”) at 11:00 a.m. CET on May 28, 2021. The Annual General Meeting will be broadcasted live. The procedures for holding the AGM have been adapted in accordance with French Ordinance No. 2020-321 of 25 March 2020 (as modified by French Ordinance n°2020-1497 of December 2, 2020) and French Decree No. 2020-418 of April 10, 2020 (as modified by French Decree No. 2020-1614 of December 18, 2020), extended by French Decree No. 2021-55 of ...

Yahoo | April 21, 2021

NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF APRIL 1, 2021

Marseille, France, April 19, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at April 1, 2021: Total number of shares outstanding:78,996,240 ordinary shares 6,806 Preferred Shares 2016 7,581 Preferred Shares 2017Total number of theoretical voting rights (1): Total number of exercisable voting rights (2):79,799,621 79,781,046 (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shar...

Yahoo | April 19, 2021

Innate Pharma Reports Full Year 2020 Financial(1) Results and Business Update - Stocks News Feed

Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma Company’s first NK cell engager selected by Sanofi as drug candidate for development Monalizumab advanced to a Phase 3 clinical trial in combination with cetuximab in IO-pretreated head and neck cancer patients;… Read More »Innate Pharma Reports Full Year 2020 Financial(1) Results and Business Update

Stocks News Feed | March 18, 2021

Innate Pharma Reports Full Year 2020 Financial(1) Results and Business Update

Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphomaCompany’s first NK cell engager selected by Sanofi as drug candidate for developmentMonalizumab advanced to a Phase 3 clinical trial in combination with cetuximab in IO-pretreated head and neck cancer patients; triggered $50 million milestone payment from AstraZenecaUS and EU Lumoxiti commercialization rights returning to AstraZenecaCash position of €190.6 million2 as of December 31, 2020 MARSEILLE, France, March 18, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the year endin...

Yahoo | March 18, 2021

Innate Pharma reports Full Year 2020 financial results and business update

Marseille, March 18, 2021 (GLOBE NEWSWIRE) -- Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphomaCompany’s first NK cell engager selected by Sanofi as drug candidate for developmentMonalizumab advanced to a Phase 3 clinical trial in combination with cetuximab in IO-pretreated head and neck cancer patients; triggered $50 million milestone payment from AstraZenecaUS and EU Lumoxiti commercialization rights returning to AstraZenecaCash position of €190.6 million2 as of December 31, 2020 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the year ending Decemb...

Yahoo | March 18, 2021

Innate Pharma Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis

Innate Pharma announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily | March 16, 2021

QuestEx Gold & Copper Announces 2020 Exploration Results from their 100% Owned Sofia Property and Delineation of 2021 Drill-Ready Targets

9, 2021 /CNW/ - QUESTEX GOLD & COPPER LTD. (TSX-V: QEX) ("QuestEx" or the "Company") is pleased to announce the results from a 2020 exploration program on its 100% owned 91 square-kilometre ("km") Sofia property in British Columbia's prolific Toodoggone Mining District (Figure 1).

Yahoo | February 9, 2021

Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients

Innate Pharma SA's (NASDAQ: IPHA) ongoing TELLOMAK Phase 2 trial, evaluating lacutamab has reached the pre-determined number of responses needed to advance to stage 2, thus allowing Innate to recruit additional patients. The company expects to present the preliminary data from this cohort at a scientific meeting this year. The study is expected to recruit up to 150 patients. Recruitment in cohort 3 is ongoing, evaluating lacutamab as monotherapy in KIR3DL2 non-expressing mycosis fungoides, the most common form of a type of blood cancer called cutaneous T-cell lymphoma. The company also plans to initiate two parallel trials to evaluate lacutamab in KIR3DL2-expressing patients with relapsed/refractory peripheral T-cell lymphoma, including a Company-sponsored Phase 1b trial to evaluate lac...

Yahoo | February 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5785 seconds.